Senseonics Announces Capital Grants to Employees as Part of Incentive Plan | Business

0


[ad_1]

GERMANTOWN, Maryland – (BUSINESS WIRE) – July 2, 2021–

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of an implantable long-term continuous glucose monitoring (CGM) system for people with diabetes, announced that it had provided capital grants to new employees as part of its 2019 Incentive Plan (the “Plan”) in accordance with section 711 (a) of the NYSE American Company Guide.

On July 1, 2021, the Senseonics Compensation Committee granted 5 new non-executive employees unqualified stock options to purchase a total of 66,000 common shares of the Company in order to induce these employees to join the Society. The options have an exercise price of $ 3.50 per share, which was the closing price of the Company’s common shares on the NYSE American on July 1, 2021. In each case, 25% of the shares underlying the options will vest on the first anniversary of the employee’s commencement date, the remainder being accrued in monthly installments over the following three-year period, in any event subject to that employee’s continued service with the Company on the applicable acquisition date. Senseonics continues to work to bring its Eversense CGM system to more people with diabetes in the United States and other markets around the world and strives to develop improvements to the system.

About Eversense

The Eversense® Continuous Glucose Monitoring System (CGM) is indicated for continuously measuring glucose levels in people 18 years of age and older with diabetes for up to 90 days. The system is indicated to be used to replace finger glucose (BG) readings for diabetes treatment decisions. Finger blood glucose readings are still needed for twice daily calibration and when symptoms do not match CGM information or when taking tetracycline class drugs. The sensor insertion and removal procedures are performed by a healthcare provider. The Eversense CGM System is a prescription device; patients should speak to their health care provider to find out more. For important safety information, see https://eversensediabetes.com/safety-info/.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational blood glucose monitoring products designed to help people with diabetes live their lives with confidence and ease. Senseonics’ CGM systems, Eversense ® and Eversense ® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn on the sensor. Blood glucose data is automatically sent every 5 minutes to a mobile app on the user’s smartphone.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210702005384/en/

CONTACT: Contact Investors Senseonics

Lynn Lewis or Philip Taylor

Investor Relations

415-937-5406

[email protected]

KEYWORD: MARYLAND UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: MEDICAL DEVICES FOR THE HEALTH OF DIABETES

SOURCE: Senseonics Holdings, Inc.

Copyright Business Wire 2021.

PUB: 07/02/2021 16:05 / DISC: 07/02/2021 16:06

http://www.businesswire.com/news/home/20210702005384/en

Copyright Business Wire 2021.

[ad_2]

Share.

About Author

Leave A Reply